In 2002, CU Professors Bob Sievers and John Carpenter, together with Dr. Brian Quinn, founded Aktiv-Dry, LLC. The purpose of the company is to commercialize the use of supercritical carbon dioxide to form micro- and nano-scale particles of thermally sensitive compounds. The pharmaceutical industry is creating a demand for fine dry powders of micron size particles to be used as active ingredients for inhalation therapies that deposit drugs deep within the alveoli of the lungs. In addition, finely divided nano- and microparticles will be used to increase the bioavailability of drugs that are often ineffective due to their low solubility or large molecular sizes. Aktiv-Dry has been awarded an SBIR grant from the NIH for the development of inhalable IgG micropowders for immunoprophylaxis against influenza. In September 2005, Aktiv-Dry began work on a $19.5 million grant from the Foundation of the National Institutes of Health to develop a needle-free measles vaccine and inhalation device for use in developing economies where 770,000 people die each year from this disease.
Sunday, October 02, 2005
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment